The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.522
Bid: 1.50
Ask: 1.58
Change: 0.015 (0.98%)
Spread: 0.08 (5.333%)
Open: 1.50
High: 1.536
Low: 1.47
Prev. Close: 1.525
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Report for the period ended 30 June 2016

5 Aug 2016 07:00

RNS Number : 3216G
Silver Falcon PLC
05 August 2016
 

 

5 August 2016

Silver Falcon Plc

 

("SILF" or "the Company")

 

Interim Report for the period ended 30 June 2016

 

Silver Falcon Plc announces its unaudited interim results for the six-month period ended 30 June 2016.

 

Highlights

 

· Successfully admitted to trading on the Main Market of the London Stock Exchange on 9th November 2015

 

· Raised £1.5m cash (gross) through the issue of 64.9m new ordinary shares

 

· Cash balance at 30 June 2016 was £1.2m

 

· Cash balance at the date of this report is £1.2m

 

Chairman's Statement

 

I am pleased to present the Interim Report for the six months ended 30th June 2016. During the period the Company made a loss of £174,936 (six months to 31 August 2015: loss of £80,367) which is mainly attributable to professional fees incurred on the proposed acquisition of Lime Holdings Limited as announced at the end of last year and general administration expenses. 

 

Whilst the Board is unable to update shareholders on the status of any negotiations at this stage, it remains confident that it can complete a transaction that will be beneficial to all shareholders. The Board considers that there will not be any detrimental effect to its ability to close a transaction as a result of Brexit. I would like to reassure shareholders that an announcement will be made to the market as soon as circumstances allow. 

 

 

 

Geoffrey Dart

Executive Chairman

 

 

 

 

 

Responsibility Statement

 

We confirm that to the best of our knowledge:

 

· the interim financial statements have been prepared in accordance with International Accounting Standards 34, Interim Financial Reporting, as adopted by the EU; and

 

· give a true and fair view of the assets, liabilities, financial position and loss of the Company; and

 

· the Interim report includes a fair review of the information required by DTR 4.2.7R of the Disclosure and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the set of interim financial statements; and a description of the principal risks and uncertainties for the remaining six months of the year.

 

· The Interim report includes a fair review of the information required by DTR 4.2.8R of the Disclosure and Transparency Rules, being the information required on related party transactions.

 

 

 

The interim report was approved by the Board of Directors and the above responsibility statement was signed on its behalf by:

 

 

 

Geoffrey Dart

Executive Chairman

 

 

 

 

Interim Statement of Comprehensive Income

 

 

 

 

 

 

 

 

6 months to

30 June 2016

Unaudited

£

 

6 months to

 31 August 2015

Unaudited

£

10 months to 31 December 2015 Audited

£

 

 

 

 

 

 

 

 

 

 

Revenue

-

 

-

-

Administration expenses

(174,936)

 

-

(46,027)

Listing costs

-

 

 

(34,340)

Operating Profit/(Loss)

(174,936)

 

-

(80,367)

 

 

 

 

 

Profit/(Loss) before tax

(174,936)

 

-

(80,367)

Tax

-

 

-

-

Profit/(Loss) for the period

(174,936)

 

-

(80,367)

 

 

 

 

 

Profit/(Loss) for the period attributable to:

 

 

 

 

 

Owners of the Company

(174,936)

 

-

(80,367)

 

 

 

 

 

Profit/(Loss) for the period

(174,936)

 

-

(80,367)

 

 

 

 

 

Total comprehensive income attributable to:

 

 

 

 

Owners of the Company

-

 

-

-

 

 

 

 

 

Total comprehensive Profit/(Loss) for the period

(174,936)

 

-

(80,367)

 

 

 

 

 

Earnings per share

 

 

 

 

Basic and diluted earnings per share attributable to equity holders of the Company (£ per share)

(0.0027)

 

-

 

 

 

(0.005)

        
 

 

Statement of Financial Position

 

 

 

 

 

 

30 June

2016

Unaudited

£

 

 

31 August

2015

Unaudited

£

 

 

31December

2015

Audited

£

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

Other receivables

49,169

 

62,500

 

31,167

Cash and cash equivalents

1,214,901

 

6,230

 

1,323,869

Total assets

1,264,070

 

68,730

 

1,355,036

 

 

 

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

 

Capital and reserves attributable to owners of the Company

 

 

 

 

 

Ordinary shares

649,000

 

75,000

 

649,000

Share Premium

781,243

 

-

 

781,243

Retained Profits

(261,573)

 

(6,270)

 

(86,637)

 

 

 

 

 

 

 

1,168,670

 

68,730

 

1,343,606

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

Trade and other payables

95,400

 

-

 

11,430

 

 

 

 

 

 

Total liabilities

95,400

 

-

 

11,430

 

 

 

 

 

 

 

 

 

 

 

 

Total Equity and Liabilities

1,264,070

 

68,730

 

1,355,036

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Statement of Changes In Equity

 

 

 

 

Attributable to owners of the Company

 

Share

Capital

Share Premium

Retained earnings

Total

 

£

£

£

£

 

 

 

 

 

Balance as at 1 March 2015

50,000

-

(6,270)

43,730

 

 

 

 

 

Profit/(Loss) for period

-

-

(80,367)

(80,367)

Total other comprehensive income

-

 

-

-

Total comprehensive income for the period

-

-

(80,367

(80,367)

 

 

 

 

 

Transaction with owners

 

 

 

 

Issue of share capital net of issue costs

599,000

781,243

-

1,380,243

 

 

 

 

 

Balance as at 31 December 2015

649,000

781,243

(86,637)

1,343,606

 

 

 

 

 

Balance as at 1 January 2016

649,000

781,243

(86,637)

1,343,606

 

 

 

 

 

Profit/(Loss) for year

-

-

(174,936)

(174,936)

Total other comprehensive income

-

-

-

-

Total comprehensive income for the period

-

-

(174,936)

(174,936)

 

 

 

 

 

Transaction with owners

 

 

 

 

Shares issued (including issued but unpaid)

-

-

-

-

 

 

 

 

 

Total transactions with owners recognised directly in Equity

-

-

-

-

 

 

 

 

 

Balance as at 30 June 2016

649,000

781,243

(261,573)

1,168,670

 

 

 

 

 

 

 

 

 

Statement of Consolidated Cash Flows

 

 

 

 

Cash flow from operating activities

 

6 months to

30 June 2016

Unaudited

£

6 months to

31 August 2015

Unaudited

£

10 months to

31 December 2015

Audited

£

 

 

 

 

 

Profit/(Loss) for the period

 

(174,936)

-

(80,367)

Changes in working capital:

 

 

 

 

(Increase)/decrease in trade and other receivables

 

(18,002)

-

6,333

Increase in trade and other payables

 

83,970

-

11,430

Net cash flow from operating activities

 

(108,968)

-

(62,604)

Cash flows from financing activities

 

 

 

 

Proceeds from issue of share capital

 

-

-

1,380,243

 

 

 

 

 

Net cash generated from financing activities

 

-

-

1,380,243

 

 

 

 

 

Net increase/decrease in cash and cash equivalents

 

 

(108,968)

-

1,317,639

Cash and cash equivalents at beginning of the period

 

 

1,323,869

6,230

6,230

Cash and cash equivalents at end of the period

 

 

1,214,901

6,230

1,323,869

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Notes to the Unaudited Financial Statements

 

1. Basis of preparation

 

The interim financial statements have been prepared in accordance with International Accounting Standard 34 'Interim Financial Reporting'. The interim financial statements should be read in conjunction with the annual financial statements for the year ended 31 December 2015, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union.

 

Cyclicality

 

The interim results for the six months ended 30 June 2016 are not necessarily indicative of the results to be expected for the full year ending 31 December 2016. Due to the nature of the entity, the operations are not affected by seasonal variations at this stage

 

2. Financial Information

 

The interim results for the period 1 January 2016 to 30 June 2016 is unaudited. In the opinion of the Directors the interim results for the period presents fairly the financial position, and results from operations and cash flows for the period in conformity with the generally accepted accounting principles consistently applied. The interim results incorporate unaudited comparative figures for the interim period 1 March 2015 to 31 August 2015 and extracts from the audited financial statements for the period to 31 December 2015. The Company changed its accounting reference date during 2015 and on the basis that the Company's activity is not seasonal has decided to include comparatives for the interim results of the immediately preceding financial period.

 

The interim financial information set out above does not constitute statutory accounts within the meaning of the Companies Act 2006. It has been prepared on a going concern basis in accordance with the recognition and measurement criteria of International Financial Reporting Standards (IFRS) as adopted by the European Union. Except as described below, the accounting policies applied in preparing the interim financial information are consistent with those that have been adopted in the Company's 2015 audited financial statements. Statutory financial statements for the year ended 31 December 2015 were approved by the Board of Directors on 5 May 2016 and delivered to the Registrar of Companies. The report of the auditors on those financial statements was unqualified.

 

Risks and uncertainties

 

The key risks that could affect the Company's short and medium term performance and the factors that mitigate those risks have not substantially changed from those set out in the Company's 2015 audited financial statements, a copy of which is available on the Company's website: http://www.silverfalconplc.com. The Company's key risk is the maintenance of its reserves of cash and cash equivalents whilst it targets an acquisition following its listing on the London Stock Exchange.

 

Accounting Policies

 

Critical accounting estimates and judgements

 

The preparation of condensed interim financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the end of the reporting period. Due to the nature of the Company, the Directors do not believe there to be any material critical accounting estimates and judgements that were used in preparing these financial statements.

 

Changes in accounting policy and disclosures.

 

New and amended standards adopted by the Company:

 

There are no IFRSs or IFRIC interpretations that are effective for the first time for the financial year commencing 1 January 2016 that would be expected to have a material impact on the Group.

 

 

The financial information for the 6 months ended 30 June 2016 and the 6 months ended 31 August 2015 has not been audited.

 

3. Trade and Other Receivables

 

 

30 June 2016

Unaudited

31 August 2015 Unaudited

31 December 2015

Audited

 

£

£

£

VAT receivable

44,834

 

28,082

Other receivables

335

 

335

Unpaid share capital

-

62,500

-

Prepayments

4,000

 

2,750

 

49,169

62,500

31,167

 

 

 

 

 

The fair value of all receivables is the same as their carrying values stated above.

 

At 30 June 2016 all trade and other receivables were fully performing, and therefore do not require impairment. The maximum exposure to credit risk at the reporting date is the carrying value of each class of receivable mentioned above. The Company does not hold any collateral as security.

 

4. Share Capital

 

 

30 June 2016

Unaudited

31 August 2015

Unaudited

31 December 2015

Audited

Allotted and issued

£

£

£

 

 

 

 

64,900,000 ordinary shares of £0.01 each

649,000

75,000

649,000

 

On 13 November 2014, the Company issued 5,000,000 Ordinary shares of £0.01 each at par.

On 29 July 2015 the Company issued 2,499,999 Ordinary shares of £0.01 each at par. On 30 October 2015 the Company issued 14,100,00 shares of £0.01 each at par and as part of a general placing on 9th November 2015 43,300,000 new Ordinary Shares of £0.01 were issued at a premium of £0.02 per share.

 

 

 

5. Related Party Transactions

 

There were no related party transactions.

 

The Directors hold the following interests:

 

 

Director

No. of Ordinary Shares

Percentage of issued ordinary share capital

Geoffrey Dart (1)

4,800,000

7.39

Peter Redmond (2)

3,600,000

5.54

Adrian Beeston

3,350,000

5.16

 

 

 (1) Geoffrey Dart holds 2,300,000 shares through Chesterfield Capital Limited, of which he is the ultimate beneficial owner and 2,500,000 shares through Black Eagle Capital, of which he holds 45.25 per cent.

(2) Peter Redmond holds these shares through Catalyst Corporate Consultants Limited, a company of which he is the sole shareholder.

 

6. Ultimate Controlling Party

 

The Directors consider there to be no ultimate controlling party at 30 June 2016.

 

7. Approval of interim financial statements

 

The interim financial statements were approved by the Board of Directors on 5th August 2016.

 

 

** ENDS **

 

 

 

 

 

For further information please visit www.silverfalconplc.com or contact:

 

 

 

Silver Falcon PLC Tel: +44 (0) 7874 762 821

Geoffrey Dart, Timothy Le Druillenec

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR QZLFBQVFFBBB
Date   Source Headline
25th Apr 20247:00 amRNSFinal Results
28th Mar 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSPlacing to Raise US$4.2 million
16th Feb 20247:00 amRNSCBR Brain Delivery
14th Feb 20247:00 amRNSCBR Intranasal Delivery
9th Feb 20247:00 amRNSFDA Consents to Phase I Trials of HEMO-CAR-T
2nd Feb 20247:00 amRNSApproval and Issuance of U.S. Conditioning Patent
16th Jan 20247:00 amRNSSubmission of Complete Response to Clinical Hold
8th Jan 20247:00 amRNSHEMO-CAR-T Process Qualification Run Completed
28th Nov 202312:19 pmRNSPlacing to Raise £534,375
27th Nov 20237:00 amRNSCBR Expanded to Treatment of Cancer
15th Nov 20237:00 amRNSLentivirus Re-manufacturing Completed
31st Oct 20237:00 amRNSTotal Voting Rights
28th Sep 202312:28 pmRNSHalf-year Report
18th Sep 20237:00 amRNSStrategic Investment from Prevail Partners, LLC
14th Sep 20237:00 amRNSClinical Hold Lift Plan is accepted by FDA
8th Sep 20235:11 pmRNSCBR Patent Application Update
10th Jul 20237:00 amRNSFull FDA Review for HEMO-CAR-T IND
30th Jun 20234:07 pmRNSResult of Annual General Meeting
2nd Jun 20232:01 pmRNSPosting of Annual Report & Notice of AGM
2nd Jun 202311:24 amRNSClinical Hold on IND for HEMO-CAR-T
9th May 20237:00 amRNSSubmission of IND for HEMO-CAR-T
28th Apr 202310:05 amRNSEquity Incentive Pool Increase and Option Grant
28th Apr 20237:00 amRNSFinal Results for the Year Ended 31 December 2022
23rd Mar 20231:32 pmRNSHEMO-CAR-T Analytical Release Tests Completed
28th Feb 20237:00 amRNSTotal Voting Rights
7th Feb 20232:30 pmRNSAdmission of Shares to Official List
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSPlacing to Raise £4,056,250
23rd Jan 20237:00 amRNSHEMO-CAR-T 3rd Process Qualification Run Completed
16th Jan 20234:40 pmRNSSecond Price Monitoring Extn
16th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
12th Jan 20234:40 pmRNSSecond Price Monitoring Extn
12th Jan 20234:35 pmRNSPrice Monitoring Extension
12th Jan 20232:05 pmRNSSecond Price Monitoring Extn
12th Jan 20232:00 pmRNSPrice Monitoring Extension
10th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20239:05 amRNSSecond Price Monitoring Extn
9th Jan 20239:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSSingle CBR Can Treat Multiple Viruses
5th Jan 20234:40 pmRNSSecond Price Monitoring Extn
5th Jan 20234:35 pmRNSPrice Monitoring Extension
5th Jan 202311:05 amRNSSecond Price Monitoring Extn
5th Jan 202311:00 amRNSPrice Monitoring Extension
4th Jan 20237:00 amRNSHEMO-CAR-T Process Qualification Run Completed
12th Dec 20227:00 amRNSHEMO-CAR-T First PQ Run Completed
18th Nov 20223:19 pmRNSHEMO-CAR-T Process Development Runs Completed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.